Charles Schwab Investment Management Inc Eagle Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$3.34 - $5.6 $77,948 - $130,692	-23,338 Reduced 31.57%	50,589 $283,000
Q1 2024 May 08, 2024	BUY	$4.26 - $6.51 $7,007 - $10,708	1,645 Added 2.28%	73,927 $387,000
Q4 2023 Feb 06, 2024	SELL	$4.63 - $15.21 $176,273 - $579,075	-38,072 Reduced 34.5%	72,282 $378,000
Q3 2023 Nov 08, 2023	BUY	$15.21 - $22.88 $55,957 - $84,175	3,679 Added 3.45%	110,354 $1.74 Million
Q2 2023 Aug 09, 2023	SELL	$17.74 - $31.87 $25,793 - $46,338	-1,454 Reduced 1.34%	106,675 $2.07 Million
Q1 2023 May 11, 2023	SELL	$25.06 - $34.09 $1.37 Million - $1.87 Million	-54,802 Reduced 33.64%	108,129 $3.07 Million
Q4 2022 Feb 13, 2023	BUY	$24.98 - $39.77 $494,778 - $787,724	19,807 Added 13.84%	162,931 $4.76 Million
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $545,044 - $972,085	20,630 Added 16.84%	143,124 $3.78 Million
Q2 2022 Aug 15, 2022	BUY	$41.26 - $51.35 $492,231 - $612,605	11,930 Added 10.79%	122,494 $5.44 Million
Q1 2022 May 13, 2022	BUY	$44.58 - $52.6 $598,352 - $705,997	13,422 Added 13.82%	110,564 $5.47 Million
Q4 2021 Feb 11, 2022	BUY	$45.82 - $56.9 $733,074 - $910,343	15,999 Added 19.72%	97,142 $4.95 Million
Q3 2021 Nov 16, 2021	BUY	$43.79 - $55.78 $21,325 - $27,164	487 Added 0.6%	81,143 $4.53 Million
Q2 2021 Aug 16, 2021	BUY	$36.86 - $44.5 $134,649 - $162,558	3,653 Added 4.74%	80,656 $3.45 Million
Q1 2021 May 17, 2021	BUY	$40.32 - $50.97 $72,938 - $92,204	1,809 Added 2.41%	77,003 $3.22 Million
Q4 2020 Feb 16, 2021	SELL	$41.72 - $51.34 $54,194 - $66,690	-1,299 Reduced 1.7%	75,194 $3.5 Million
Q3 2020 Nov 13, 2020	BUY	$37.02 - $51.28 $307,228 - $425,572	8,299 Added 12.17%	76,493 $3.25 Million
Q2 2020 Aug 14, 2020	BUY	$43.24 - $55.02 $347,952 - $442,745	8,047 Added 13.38%	68,194 $3.27 Million
Q1 2020 May 15, 2020	SELL	$34.37 - $60.07 $1.71 Million - $2.98 Million	-49,640 Reduced 45.21%	60,147 $2.77 Million
Q4 2019 Feb 07, 2020	SELL	$54.32 - $64.31 $212,988 - $252,159	-3,921 Reduced 3.45%	109,787 $6.6 Million
Q3 2019 Nov 08, 2019	BUY	$53.25 - $59.98 $93,826 - $105,684	1,762 Added 1.57%	113,708 $6.43 Million
Q2 2019 Aug 09, 2019	BUY	$46.61 - $58.45 $657,713 - $824,787	14,111 Added 14.42%	111,946 $6.23 Million
Q1 2019 May 14, 2019	BUY	$38.66 - $51.82 $750,119 - $1.01 Million	19,403 Added 24.74%	97,835 $4.94 Million
Q4 2018 Feb 14, 2019	SELL	$36.72 - $67.73 $192,302 - $354,702	-5,237 Reduced 6.26%	78,432 $3.16 Million
Q3 2018 Nov 13, 2018	BUY	$66.65 - $83.86 $2.37 Million - $2.98 Million	35,569 Added 73.95%	83,669 $5.8 Million
Q2 2018 Aug 08, 2018	SELL	$51.25 - $76.62 $2 Million - $2.99 Million	-39,025 Reduced 44.79%	48,100 $3.64 Million
Q1 2018 May 07, 2018	BUY	$52.16 - $66.86 $1.04 Million - $1.34 Million	20,031 Added 29.86%	87,125 $4.59 Million
Q4 2017 Jan 17, 2018	BUY	$49.6 - $60.87 $316,348 - $388,228	6,378 Added 10.5%	67,094 $3.59 Million
Q3 2017 Nov 13, 2017	BUY	$46.62 - $60.36 $2.83 Million - $3.66 Million	60,716	60,716 $3.62 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account